Related Experiment Videos
CR1 activity on erythrocytes and renal glomeruli in patients with renal disorders
B M Iversen1, C A Vedeler, R Matre
1Medical Department A, Gade Institute, University of Bergen, Norway.
Insights
Reduced complement receptor type 1 (CR1) on erythrocytes is linked to systemic lupus erythematosus (SLE) and glomerulonephritis. CR1 levels improved with treatment, suggesting its role in monitoring disease activity in renal disorders.
Area of Science:
- Immunology
- Nephrology
- Complement System
Background:
- Complement receptors C3b/C4b (CR1) play a role in immune regulation.
- Erythrocyte CR1 (ECR1) and glomerular CR1 (GCR1) are key components of the complement system.
- Dysregulation of complement is implicated in various renal disorders.
Purpose of the Study:
- To investigate the activity of complement receptors CR1 on erythrocytes and renal glomeruli in patients with different renal diseases.
- To assess the correlation between CR1 activity and disease status, particularly in systemic lupus erythematosus (SLE).
- To evaluate the impact of treatment on CR1 activity in SLE patients.
Main Methods:
- Analysis of ECR1 activity in patients with IgA glomerulonephritis, benign nephrosclerosis, and other renal diseases.
- Assessment of ECR1 and GCR1 activity in patients with SLE and glomerulonephritis.
- Monitoring of CR1 activity during corticosteroid and azathioprine treatment in SLE patients.
- Examination of CR1 activity in renal transplant recipients.
Main Results:
- Normal ECR1 activity was observed in patients with IgA glomerulonephritis, benign nephrosclerosis, and other renal diseases.
- 75% of SLE and glomerulonephritis patients exhibited low or absent ECR1 activity.
- GCR1 activity was normal, except in areas with complement deposits where it was abolished.
- Successful SLE treatment correlated with increased ECR1 activity, while non-responders maintained low ECR1 levels.
- Renal transplant patients showed increased ECR1 activity.
Conclusions:
- Reduced ECR1 activity is a significant finding in patients with SLE and glomerulonephritis.
- ECR1 activity serves as a potential biomarker for monitoring therapeutic response in SLE patients.
- Complement receptor function is altered in renal diseases, with potential implications for pathogenesis and treatment monitoring.
Abstract:
Complement receptors for C3b/C4b (CRI) on erythrocytes (ERC1) and renal glomeruli (GCR1) were examined in patients with different types of renal disorders. Normal ECR1 activity was found on erythrocytes from patients with IgA glomerulonephritis, benign nephrosclerosis and other types of renal diseases. In patients with systemic lupus erythematosus (SLE) and glomerulonephritis ECR1 activity was low or absent in 75% of the patients. The GCR1 activity, however, was normal except in areas with complement deposits where GCR1 activity was abolished. During treatment with corticosteroids and azathioprine of patients with SLE the clinical response was followed by increased functional ECR1 activity. In those patients who did not respond the ECR1 activity was persistently low. Three patients with renal transplant all showed increased ECR1 activity.